NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
16th Annual World ADC London Summit – Presentation
Spotlighting Efficacy & Safety Profiles of Dual Payload ADCs Featuring Novel Linker Payloads to Overcome Resistance Mechanisms Presenter: Hans-Peter Gerber, Ph.D., Chief Scientific Officer
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SOUTH SAN FRANCISCO, Calif., December 17, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has regained compliance with...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., December 16, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the...
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
– Initial clinical data expected mid-2026 – South San Francisco, Calif. — December 3, 2025 — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),...
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board)...
Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting – Poster Presentation
Next-Generation Immunostimulatory Antibody-Drug Conjugates (iADCs) Combine Tumor Cell Killing with Immune Activation to Induce Durable Antitumor Immunity
16th Annual World ADC San Diego – Presentations
Showcasing Development of Site-Specific, High-DAR Dual-Payload ADCs Presenter: Daniel Calarese, Ph.D.Developing Next-Generation Immunostimulatory Dual Payload ADCs to Enhance Therapeutic Index & Tackle Patient Resistance Presenter: Gang Yin, Ph.D.Laying Out...
Sutro R&D Day – Presentation
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at World ADC and SITC,...
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., November 5, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research &...